The Recombinant Vaccinia Virus Gene Product,B18R,Neutralizes Interferon Alpha and Alleviates Histopathological Complications in an HIV Encephalitis Mouse Model
Restricted accessResearch articleFirst published online July, 2014
The Recombinant Vaccinia Virus Gene Product,B18R,Neutralizes Interferon Alpha and Alleviates Histopathological Complications in an HIV Encephalitis Mouse Model
Interferon-alpha (IFN-α) has been identified as a neurotoxin that plays a prominent role in human immunodeficiency virus (HIV)-associated neurocognitive disorders and HIV encephalitis (HIVE) pathology. IFN-α is associated with cognitive dysfunction in other inflammatory diseases where IFN-α is upregulated. Trials of monoclonal anti-IFN-α antibodies have been generally disappointing possibly due to high specificity to limited IFN-α subtypes and low affinity. We investigated a novel IFN-α inhibitor, B18R, in an HIVE/severe combined immunodeficiency (SCID) mouse model. Immunostaining for B18R in systemically treated HIVE/SCID mice suggested the ability of B18R to cross the blood–brain barrier (BBB). Real-time PCR indicated that B18R treatment resulted in a decrease in gene expression associated with IFN-α signaling in the brain. Mice treated with B18R were found to have decreased mouse mononuclear phagocytes and significant retention of neuronal arborization compared to untreated HIVE/SCID mice. Increased mononuclear phagocytes and decreased neuronal arborization are key features of HIVE. These results suggest that B18R crosses the BBB, blocks IFN-α signaling, and it prevents key features of HIVE pathology. These data suggest that the high affinity and broad IFN-α subtype specificity of B18R make it a viable alternative to monoclonal antibodies for the inhibition of IFN-α in the immune-suppressed environment.
Get full access to this article
View all access options for this article.
References
1.
AlcamiA.S.J.A.S.G.L. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol, 74(23):11230–11239.
BoderET, MidelfortKS, WittrupKD. 2000. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A, 97(20):10701–10705.
4.
BrewBJ, HalmanM, CatalanJ, SacktorN, PriceRW, BrownS, AtkinsonH, CliffordDB, SimpsonD, TorresG, HallC, PowerC, MarderK, McArthurJC, SymondsW, RomeroC. 2007. Factors in AIDS dementia complex trial design: Results and lessons from the abacavir trial. PLoS Clin Trials, 2(3):e13
5.
CliffordDB, McArthurJC, SchifittoG, KieburtzK, McDermottMP, LetendreS, CohenBA, MarderK, EllisRJ, MarraCM. 2002. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology, 59(10):1568–1573.
6.
CookJE, DasguptaS, MiddaughLD, TerryEC, GorryPR, WesselinghSL, TyorWR. 2005. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol, 57(6):795–803.
7.
Cook-EasterwoodJ, MiddaughLD, GriffinWC3rd, KhanI, TyorWR. 2007. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol, 205(2):506–512.
8.
EllisRJ, RosarioD, CliffordDB, McArthurJC, SimpsonD, AlexanderT, GelmanBB, VaidaF, CollierA, MarraCM, AncesB, AtkinsonJH, DworkinRH, MorgelloS, GrantI, GroupCS. 2010. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol, 67(5):552–558.
GenisP, JettM, BerntonEW, BoyleT, GelbardHA, DzenkoK, KeaneRW, ResnickL, MizrachiY, VolskyDJ, EpsteinLG, GendelmanHE. 1992. Cytokines and arachidonic metabolites produced during human-immunodeficiency-virus (HIV)-infected macrophage-astroglia interactions—implications for the neuropathogenesis of HIV disease. J Exp Med, 176(6):1703–1718.
11.
GlassJD, WesselinghSL. 2001. Microglia in HIV-associated neurological diseases. Microsc Res Tech, 54(2):95–105.
12.
GoodkinK, VitielloB, LymanWD, AsthanaD, AtkinsonJH, HeseltinePN, MolinaR, ZhengW, KhamisI, WilkieFL, ShapshakP. 2006. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol, 12(3):178–189.
13.
GringeriA, MusiccoM, HermansP, BentwichZ, CusiniM, BergamascoA, SantagostinoE, BurnyA, BizziniB, ZaguryD. 1999. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1—infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol, 20(4):358–370.
14.
HemmerB, StuveO, KieseierB, SchellekensH, HartungHP. 2005. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol, 4(7):403–412.
15.
HiggsBW, ZhuW, MorehouseC, WhiteWI, BrohawnP, GuoX, RebelattoM, LeC, AmatoA, FiorentinoD, GreenbergSA, DrappaJ, RichmanL, GrethW, JallalB, YaoY. 2013. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis, 73(1):256–262.
16.
HuangJ, SmirnovSV, Lewis-AntesA, BalanM, LiW, TangS, SilkeGV, PutzMM, SmithGL, KotenkoSV. 2007. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A, 104(23):9822–9827.
17.
KelderW, McArthurJC, Nance-SprosonT, McClernonD, GriffinDE. 1998. beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol, 44(5):831–835.
KrivineA, ForceG, ServanJ, CabeeA, RozenbergF, DighieroL, MarguetF, LebonP. 1999. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. J Neurovirol, 5(5):500–506.
20.
LeroyV, BaudM, de TraversayC, Maynard-MuetM, LebonP, ZarskiJP. 1998. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol, 28(3):375–381.
21.
LinerKJ2nd, RoMJ, RobertsonKR. 2010. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep, 7(2):85–91.
22.
LiptakovaH, KontsekovaE, AlcamiA, SmithGL, KontsekP. 1997. Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2. Virology, 232(1):86–90.
23.
LivakKJ, SchmittgenTD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods, 25(4):402–408.
24.
LouboutinJP, StrayerDS. 2012. Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications. ScientificWorldJournal, 2012:482575
MarounLE, HeffernanTN, HallamDM. 2000. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. J Interferon Cytokine Res, 20(2):197–203.
27.
MasliahE, RobertsES, LangfordD, EverallI, CrewsL, AdameA, RockensteinE, FoxHS. 2004. Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol, 157(1–2):163–175.
28.
McArthurJC, SteinerJ, SacktorN, NathA. 2010. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol, 67(6):699–714.
29.
NakasujjaN, MiyaharaS, EvansS, LeeA, MusisiS, KatabiraE, RobertsonK, RonaldA, CliffordDB, SacktorN. 2013. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology, 80(2):196–202.
30.
PetriM, WallaceDJ, SpindlerA, ChindaloreV, KalunianK, MyslerE, NeuweltCM, RobbieG, WhiteWI, HiggsBW, YaoY, WangL, EthgenD, GrethW. 2013. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum, 65(4):1011–1021.
31.
PotterMC, Figuera-LosadaM, RojasC, SlusherBS. 2013. Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol, 8(3):594–607.
32.
RhoMB, WesselinghS, GlassJD, McArthurJC, ChoiS, GriffinJ, TyorWR. 1995. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun, 9(4):366–377.
33.
SacktorNC, SkolaskyRL, LylesRH, EspositoD, SelnesOA, McArthurJC. 2000. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol, 6(1):84–88.
SasAR, Bimonte-NelsonHA, TyorWR. 2007. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS, 21(16):2151–2159.
36.
ScheibelRS, ValentineAD, O'BrienS, MeyersCA. 2004. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci, 16(2):185–191.
37.
SchifittoG, PetersonDR, ZhongJ, NiH, CruttendenK, GaughM, GendelmanHE, BoskaM, GelbardH. 2006. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology, 66(6):919–921.
38.
SchifittoG, SacktorN, MarderK, McDermottMP, McArthurJC, KieburtzK, SmallS, EpsteinLG. 1999. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology, 53(2):391–396.
39.
SymonsJA, AlcamiA, SmithGL. 1995. Vaccinia virus encodes a soluble type-I interferon receptor of novel structure and broad species-specificity. Cell, 81(4):551–560.
40.
ThorpeR, FRCPath, WadhwaM. 2013. New CHMP Guideline on immunogenicity of monoclonal antibodies. Generics and Biosimilars Initiative Journal, 2(1):45–46.
41.
TyorWR. 2009. Pathogenesis and treatment of HIV-associated dementia: recent studies in a SCID mouse model. In: BanikN, ed. Handbook of Neurochemistry and Molecular Neurobiology. Heidelberg, Germany: Springer-Verlag Berlin, pp. 472–489.
42.
TyorWR, GlassJD, GriffinJW, BeckerPS, McArthurJC, BezmanL, GriffinDE. 1992. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol, 31(4):349–360.
43.
TyorWR, PowerC, GendelmanHE, MarkhamRB. 1993. A model of human immunodeficiency virus encephalitis in SCID mice. Proc Natl Acad Sci U S A, 90(18):8658–8662.
44.
ValentineAD, MeyersCA, KlingMA, RichelsonE, HauserP. 1998. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol, 25(1 Suppl 1):39–47.
45.
WileyCA, AchimC. 1994. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol, 36(4):673–676.
46.
YangJ, HuD, XiaJ, LiuJ, ZhangG, GendelmanHE, BoukliNM, XiongH. 2013. Enhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathology. J Neuroimmune Pharmacol, 8(4):921–933.
